Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors within the central anxious program, conolidine modulates alternate molecular targets. A Science Improvements research discovered that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide... https://frede429abu8.answerblogs.com/profile